Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05866289 Completed - Oxygen Deficiency Clinical Trials

Awake Prone Positioning for COVID-19 Acute Hypoxaemic Respiratory Failure

Start date: March 1, 2020
Phase:
Study type: Observational [Patient Registry]

The objective of our study is to evaluate the effectiveness of prone position in preventing intubation or death in spontaneously ventilated patients with COVID-19 with acute respiratory failure.

NCT ID: NCT05866263 Completed - COVID-19 Clinical Trials

Investigation of the Effect on Cognitive Skills of COVID-19 Survivors

Cognitive
Start date: March 23, 2021
Phase: N/A
Study type: Interventional

Investigation of the Effect Of Green Walking and Intelligence Games on the Cognitive Skills of Individuals Between the Ages of 50-70 Survived COVID-19 Disease The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.

NCT ID: NCT05866224 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Telerehabilitation Program and Detraining in Patients With Post-COVID-19 Sequelae

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the effects of a 15-week home telerehabilitation program and a detraining period on cardiorespiratory fitness and muscular efficiency in patients with post-COVID-19 sequelae compared to a control group of COVID-19 patients. We hypothesize that cardiorespiratory fitness and muscular efficiency significantly improve in patients who carry out the home telerehabilitation program. However, the cardiorespiratory and muscular adaptations achieved and tolerance to exercise are lost over time as an effect of detraining.

NCT ID: NCT05863429 Completed - COVID-19 Infection Clinical Trials

Observational National Vaccine Study

Start date: May 18, 2022
Phase:
Study type: Observational [Patient Registry]

To assess the long-term safety of TURKOVAC in individuals who have not previously received the COVID-19 vaccine or who have received their primary vaccination with inactivated or mRNA vaccine, or who have received their primary vaccination with similarly inactivated or mRNA vaccine and who subsequently received the first dose or second dose of booster vaccine, who meet the inclusion/exclusion criteria of the study.

NCT ID: NCT05862883 Completed - Clinical trials for COVID-19 Respiratory Infection

Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

Clinical research includes Determination of efficacy and acceptability of the local medicine "Rutan tablets 0,025" in children and teenagers 6-18 years old with COVID-19 and/or acute respiratory viral infections. And also the purpose of the study was to study clinical and laboratory changes when using Rutan in patients with Covid 19 clinical methods such as collection of anamnesis, dynamic examination of patients, catamnestic observation - a telephone survey, as well as biochemical, immunological, virologic PCR and ELISA tests.

NCT ID: NCT05859958 Completed - COVID-19 Clinical Trials

ABO Blood Group Type Association With COVID-19 Severity

Start date: November 10, 2022
Phase:
Study type: Observational

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

NCT ID: NCT05859919 Completed - Clinical trials for Patients With COVID-19

Conducting Clinical Trials of the Medicine "Rutan Tablets 0.1g" No. 10 in the Complex Therapy of COVID-19

Start date: October 12, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of the registered drug Rutan 0.1 against SARS-CoV-2 in patients with COVID-19. The main group (30 people) - patients with COVID-19 who are on inpatient treatment who were prescribed the drug Rutan 0.1, 1 tablet 2 times a day for 10 days. The control group (27 people) - patients with COVID-19 who are hospitalized and received therapy according to the National Temporary Protocol for the management of patients with COVID-19.

NCT ID: NCT05859893 Completed - Stress Clinical Trials

Therapeutic Melodies: How Classical Turkish Music Soothes Stress and Eases Loneliness

Start date: June 3, 2020
Phase: N/A
Study type: Interventional

This study investigated the impact of traditional classical Turkish music as a telehealth intervention on reducing stress and loneliness among elderly individuals.

NCT ID: NCT05858450 Completed - COVID-19 Clinical Trials

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Start date: May 5, 2023
Phase:
Study type: Observational

This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.

NCT ID: NCT05857176 Completed - Clinical trials for COVID-19 Vaccine Adverse Reaction

Assessment of Safety and Satisfaction Toward COVID-19 Vaccines.

Start date: December 15, 2021
Phase:
Study type: Observational

This is a cross-sectional, web-based online survey done with the use of a Google Form-questionnaire to gather information from the general public regarding their knowledge, satisfaction, and tolerability about the COVID-19 vaccine.